CO6592104A2 - Compuesto heterociclico - Google Patents

Compuesto heterociclico

Info

Publication number
CO6592104A2
CO6592104A2 CO12158066A CO12158066A CO6592104A2 CO 6592104 A2 CO6592104 A2 CO 6592104A2 CO 12158066 A CO12158066 A CO 12158066A CO 12158066 A CO12158066 A CO 12158066A CO 6592104 A2 CO6592104 A2 CO 6592104A2
Authority
CO
Colombia
Prior art keywords
heterocyclic compound
compound
salt
useful
cancer
Prior art date
Application number
CO12158066A
Other languages
English (en)
Inventor
Misaki Homma
Toru Miyazaki
Yuya Oguro
Osamu Karasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6592104(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6592104A2 publication Critical patent/CO6592104A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto útil como un agente profiláctico o terapéutico para cáncer. Se describe específicamente un compuesto representado por la fórmula (1) (en donde cada símbolo es como se define en la descripción) o una sal del mismo, o un promedicamento del compuesto o la sal del mismo, el cual es útil para la prevención o tratamiento de cáncer.
CO12158066A 2010-02-17 2012-09-13 Compuesto heterociclico CO6592104A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010131950 2010-06-09

Publications (1)

Publication Number Publication Date
CO6592104A2 true CO6592104A2 (es) 2013-01-02

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12158066A CO6592104A2 (es) 2010-02-17 2012-09-13 Compuesto heterociclico

Country Status (35)

Country Link
US (6) US8722660B2 (es)
EP (2) EP2540728B1 (es)
JP (1) JP5689454B2 (es)
KR (1) KR101735868B1 (es)
CN (1) CN102844320B (es)
AU (1) AU2011216404B2 (es)
BR (1) BR112012020311B1 (es)
CA (1) CA2790284C (es)
CL (1) CL2012002250A1 (es)
CO (1) CO6592104A2 (es)
CR (1) CR20120448A (es)
CY (1) CY1121792T1 (es)
DK (1) DK2540728T3 (es)
DO (1) DOP2012000224A (es)
EA (1) EA020724B1 (es)
EC (1) ECSP12012160A (es)
ES (1) ES2733221T3 (es)
GE (1) GEP20146202B (es)
HR (1) HRP20190947T1 (es)
HU (1) HUE043514T2 (es)
IL (1) IL221442A0 (es)
LT (1) LT2540728T (es)
MA (1) MA34064B1 (es)
ME (1) ME03410B (es)
MX (1) MX353500B (es)
MY (1) MY164776A (es)
NZ (1) NZ602089A (es)
PE (1) PE20130184A1 (es)
PL (1) PL2540728T3 (es)
PT (1) PT2540728T (es)
RS (1) RS58796B1 (es)
SG (1) SG183304A1 (es)
SI (1) SI2540728T1 (es)
TN (1) TN2012000401A1 (es)
WO (1) WO2011102399A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021696A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3100742B1 (en) 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
CA3090392C (en) 2015-12-07 2021-06-01 Zymergen Inc. Microbial strain improvement by a htp genomic engineering platform
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
EP3436463B1 (en) * 2016-03-28 2021-06-23 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
ES2877140T3 (es) 2016-11-08 2021-11-16 Cancer Research Tech Ltd Derivados de pirimidinona como inhibidores de Cdc7
WO2018158898A1 (en) 2017-03-01 2018-09-07 Takeda Pharmaceutical Company Limited Method of predicting effects of cdc7 inhibitor
JP6825163B2 (ja) * 2017-05-21 2021-02-03 ゼンジ リサーチ ラボラトリーズＺｅｎｊｉ Ｒｅｓｅａｒｃｈ Ｌａｂｏｒａｔｏｒｉｅｓ 抗癌剤としての置換［５，６］シクロ−４（３ｈ）−ピリミジノン
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
CN111989331B (zh) * 2018-04-02 2024-04-12 武田药品工业株式会社 2-[(2S)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1H-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3H)-酮的合成方法
TW202016316A (zh) 2018-06-19 2020-05-01 日商武田藥品工業股份有限公司 癌症治療方法
AU2019305828A1 (en) * 2018-07-19 2021-01-28 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a CDC7 inhibitor
MX2021014629A (es) * 2019-05-30 2022-02-23 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuestos tetraciclicos como inhibidores de cdc7.
CN114126621A (zh) * 2019-07-19 2022-03-01 武田药品工业株式会社 用于癌症治疗的组合疗法
EP4006036A4 (en) * 2019-08-20 2022-09-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TETRACYCLIC COMPOUND USED AS A CDC7 INHIBITOR
EP4069369A4 (en) * 2019-12-06 2024-02-14 Schroedinger Inc CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
US20230365584A1 (en) * 2020-09-10 2023-11-16 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
WO2022111729A1 (zh) * 2020-11-30 2022-06-02 正大天晴药业集团股份有限公司 作为Cdc7抑制剂的盐型及其晶型
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
US20240173323A1 (en) 2021-02-08 2024-05-30 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
WO2023064879A1 (en) * 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
KR20030034232A (ko) 2000-09-29 2003-05-01 닛뽕소다 가부시키가이샤 티에노피리미딘 화합물 및 그 염 및 제조방법
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2002085909A1 (en) 2001-04-20 2002-10-31 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
EP1537112B1 (en) 2002-08-06 2006-04-19 Astrazeneca AB Condensed pyridines and pyrimidines with tie2 (tek) activity
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
ES2324536T7 (es) * 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA06001556A (es) * 2003-08-08 2006-05-15 Pharmacia Italia Spa Derivados activos de pirimidilpirrol como inhibidores de la cinasa.
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
US7470701B2 (en) 2004-03-30 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Substituted 2,5-heterocyclic derivatives
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
EP1856128A4 (en) 2005-01-19 2009-12-23 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
EP1932841B1 (en) 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) * 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007102679A1 (en) 2006-03-06 2007-09-13 Je Il Pharmaceutical Co., Ltd. Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US20090030196A1 (en) * 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20110182881A1 (en) 2008-06-26 2011-07-28 Dana-Farber Cancer Institute, Inc. Signature and determinants associated with metastasis and methods of use thereof
WO2010101302A1 (en) 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011029782A1 (en) 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
EP2540728A1 (en) 2013-01-02
PL2540728T3 (pl) 2019-09-30
CN102844320B (zh) 2016-03-23
BR112012020311A2 (pt) 2017-03-01
SG183304A1 (en) 2012-09-27
ME03410B (me) 2020-01-20
MX2012009602A (es) 2012-12-17
GEP20146202B (en) 2014-11-25
CL2012002250A1 (es) 2013-02-08
SI2540728T1 (sl) 2019-06-28
KR101735868B1 (ko) 2017-05-15
US20150158882A1 (en) 2015-06-11
WO2011102399A1 (ja) 2011-08-25
US8933069B2 (en) 2015-01-13
US20130029969A1 (en) 2013-01-31
ECSP12012160A (es) 2013-03-28
US8722660B2 (en) 2014-05-13
RS58796B1 (sr) 2019-07-31
MY164776A (en) 2018-01-30
KR20130001246A (ko) 2013-01-03
PT2540728T (pt) 2019-07-11
DK2540728T3 (da) 2019-05-13
EP3533797B1 (en) 2023-12-20
EP2540728B1 (en) 2019-04-10
TN2012000401A1 (en) 2014-01-30
MA34064B1 (fr) 2013-03-05
EP3533797A1 (en) 2019-09-04
ES2733221T3 (es) 2019-11-28
JP5689454B2 (ja) 2015-03-25
CR20120448A (es) 2012-11-13
CN102844320A (zh) 2012-12-26
PE20130184A1 (es) 2013-03-09
IL221442A0 (en) 2012-10-31
US9388195B2 (en) 2016-07-12
US8921354B2 (en) 2014-12-30
US20170209452A1 (en) 2017-07-27
US9655900B2 (en) 2017-05-23
DOP2012000224A (es) 2013-01-31
CA2790284A1 (en) 2011-08-25
US20140235615A1 (en) 2014-08-21
CA2790284C (en) 2019-01-08
MX353500B (es) 2018-01-16
JPWO2011102399A1 (ja) 2013-06-17
LT2540728T (lt) 2019-06-25
EA020724B1 (ru) 2015-01-30
NZ602089A (en) 2014-05-30
EA201290800A1 (ru) 2013-03-29
EP2540728A4 (en) 2013-11-06
CY1121792T1 (el) 2020-07-31
US20160310494A1 (en) 2016-10-27
BR112012020311B1 (pt) 2019-01-29
AU2011216404B2 (en) 2016-04-07
US20140228352A1 (en) 2014-08-14
HUE043514T2 (hu) 2019-08-28
HRP20190947T1 (hr) 2019-07-26
AU2011216404A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
CO6592104A2 (es) Compuesto heterociclico
EA201400178A1 (ru) Лечение рака молочной железы
CR20140537A (es) Compuesto heterocíclico nitrogenado
ECSP10010526A (es) Compuesto heterociclico
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
PH12015501058A1 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
EA201171367A1 (ru) Винилиндазолильные соединения
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX361499B (es) Baricitinib deuterado.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015501088A1 (en) Dimeric compounds
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
PH12015500399A1 (en) Azaindolines
EA201491581A1 (ru) Везикулярные композиции
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
MX2015012610A (es) Pacritinib deuterizado.
UY35095A (es) Compuestos heterocíclicos que contienen nitrógeno
UY32088A (es) Compuesto heterociclico
CL2014001265A1 (es) Compuestos derivados de uracilo, inhibidores de la quinasa axl y c-met, utiles en el tratamiento del cancer.
ECSP14026022A (es) Compuesto heterocíclico nitrogenado

Legal Events

Date Code Title Description
FG Application granted